DUPIXENT® (dupilumab) for Eosinophilic Esophagitis Patients

Addresses two key sources underlying type 2 inflammation in EoE^1,2,a

Discover the moa

NOT AN IMMUNOSUPPRESSANT¹

^aThe mechanism of dupilumab action has not been definitvely established.¹

Studied across clinical, histologic, and endoscopic endpoints^1,3,4

View the results

Demonstrated safety profile¹

review the data

MOA, mechanism of action.

Weekly dosing¹

see dosage and administration

Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

LEARN HOW WE CAN HELP

*DUPIXENT MyWay* ENROLLMENT FORMS
FOR GASTRENOLOGISTS
English Enrollment Form
Spanish Enrollment Form
FOR ALLERGISTS
Allergist (EoE) English Enrollment Form
Allergist (EoE) Spanish Enrollment Form

Contact a Field Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

CONTACT A REP

THE FIRST AND ONLY
FDA-APPROVED EoE THERAPY

Addresses two key sources underlying type 2 inflammation in EoE^1,2,a

Studied across clinical, histologic, and endoscopic endpoints^1,3,4

Demonstrated safety profile¹

Weekly dosing¹

DUPIXENT MyWay
ENROLLMENT FORMS

THE FIRST AND ONLY FDA-APPROVED EoE THERAPY

Addresses two key sources underlying type 2 inflammation in EoE1,2,a

Studied across clinical, histologic, and endoscopic endpoints1,3,4

Demonstrated safety profile1

Weekly dosing1

DUPIXENT MyWay ENROLLMENT FORMS

Are you sure you want to leave?

Are you sure you want to leave?

THE FIRST AND ONLY
FDA-APPROVED EoE THERAPY

Addresses two key sources underlying type 2 inflammation in EoE^1,2,a

Studied across clinical, histologic, and endoscopic endpoints^1,3,4

Demonstrated safety profile¹

Weekly dosing¹

DUPIXENT MyWay
ENROLLMENT FORMS